APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S.340/HR 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; H.R. 1506, the Fair And Immediate Release of Generic Drugs Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods; HR 938, the Bringing Low-cost Options and Competition While Keeping Incentives for New Generics Act, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; HR 987, Strengthening Health Care and Lowering Prescription Drug Costs, Title I, Subtitle A, Section 101, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; S. 1895-Lower Health Care Costs Act Section 205, Preventing Blocking of Generic Drugs, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework; Federal policy relating to pharmaceutical market blockages caused by parked Hatch-Waxman 180-day exclusivity periods; and HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, provisions relating to patent settlements between brand and generic drug companies.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.